Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta-analysis.

"data s1 acknowledgments we thank the authors who re-examined the data and shared additional information with us for this project with special thanks to chang gon kim md phd (yonsei cancer center); won-mook choi md phd (asan medical center); inhwan hwang md (daejeon eulji medical center); yoshiaki nakamura md phd (national cancer center hospital east); akinori sasaki md phd (tokyo bay urayasu ichikawa medical center); shuixing zhang md phd (the first affiliated hospital of jinan university); emiliano calvo md phd (start madrid-centro integral oncologico clara campal hospital); kyung hwan kim md phd (yonsei cancer center); hugo arasanz esteban md phd (hospital universitario de navarra); pablo ayala de miguel md (university hospital san pedro de alcantara) koichi azuma md phd (kurume university school of medicine); deirdre m h j ten berge (erasmus university medical center); bernhard scheiner md phd (medical university of vienna); and ryusuke nakamoto md phd (kyoto university hospital). data availability statement the data used in this study can be found in the figshare"

"CONFLICT OF INTEREST STATEMENT Dr. Chae reports receiving a research grant to the institution from Abbvie, BMS, Biodesix, Lexent Bio, and Freenome; he has also received honoraria from or is in advisory boards for Roche/Genentech, BMS, AstraZeneca, Merck, Foundation Medicine, Counsyl, Neogenomics, Guardant Health, Boehringher Ingelheim, Biodesix, Immuneoncia, Lilly Oncology, Merck, Takeda, Pfizer, Tempus, Lunit, and Jazz Pharmaceuticals."

"FUNDING INFORMATION The author(s) received no specific funding for this work."